Analgesic nephropathy epidemiology and demographics
Analgesic nephropathy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Analgesic nephropathy epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Analgesic nephropathy epidemiology and demographics |
Analgesic nephropathy epidemiology and demographics in the news |
Blogs on Analgesic nephropathy epidemiology and demographics |
Risk calculators and risk factors for Analgesic nephropathy epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
There is insufficient evidence about the incidence, prevalence and racial predilection of analgesic nephropathy. Most patients with analgesic nephropathy have been reported to be middle age or older with a history of chronic pain. There is insufficient evidence that suggests gender predilection in analgesic nephropathy. However, some studies suggest that analgesic nephropathy is more conman in females than males.
Epidemiology and Demographics
Incidence
There is insufficient evidence about the incidence of analgesic nephropathy.
Prevalence
There is insufficient evidence about the prevalence of analgesic nephropathy.
Age
Most patients with analgesic nephropathy have been reported to be middle age or older with a history of chronic pain.[1]
Race
There is insufficient evidence that suggests racial predilection in analgesic nephropathy.
Gender
There is insufficient evidence that suggests gender predilection in analgesic nephropathy. However, some studies suggest that analgesic nephropathy is more conman in females than males. [2]
References
- ↑ Yaxley J (2016). "Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence". Int J Risk Saf Med. 28 (4): 189–196. doi:10.3233/JRS-170735. PMID 28582877.
- ↑ Gault MH, Wilson DR (1978). "Analgesic nephropathy in Canada: clinical syndrome, management, and outcome". Kidney Int. 13 (1): 58–63. doi:10.1038/ki.1978.8. PMID 713269.